---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-141341"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:53:27.875425+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AlloVir Q1 net loss $43.9M; advances posoleucel to Phase 3 multi-virus prevention

## Summary
- Net loss $43.9M ($0.69/share) vs $30.9M ($0.50) in Q1 2021; R&D spend $29.1M.
- Cash, equivalents & marketable securities $201.4M, down from $248.1M at year-end 2021.
- Initiated global Phase 3 registrational study of posoleucel to prevent 6 viruses in allo-HCT patients.
- FDA granted third RMAT designation for posoleucel multi-virus prevention; estimated addressable population 40,000 patients/year.
- FY2022 operating expense guidance reaffirmed at $130M–$145M excluding stock-based compensation.

## SEC filing metadata
- accession: 0001193125-22-141341
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312522141341/0001193125-22-141341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312522141341/d339026d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-141341
- JSON: https://secwatch.observer/filing/0001193125-22-141341.json
- Plain text: https://secwatch.observer/filing/0001193125-22-141341.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.